

organized by:



under the auspices:



Melanoma Bridge



Naples, Royal Continental Hotel
December 5th - 8th, 2013

PRELIMINARY PROGRAM

DECEMBER 5TH- 6TH 2013

DECEMBER 5TH 2013

- 17:00 Opening Ceremony
Patients meet the melanoma experts
Valerie Guild, AIM at Melanoma*
Fondazione Melanoma Onlus representative
Regione Campania representative
Comune di Napoli representative

DECEMBER 6TH 2013

DIAGNOSIS AND NEW PROCEDURES

Chair: Howard L. Kaufman and Nicola Mozzillo

- 9:30 The role of melanoma genetic testing in prevention and early detection
Sancy Leachman
- 9:55 How should melanoma patients be followed-up?
Clause Garbe
- 10:20 Clinically important data from gene microarray studies of melanocytic lesions
Alistair Cochran
- 10:45 AJCC classification, the Melanoma Cancer Genome Atlas Program (TCGA), and beyond:
Integrated models in the molecular era
Jeffrey Gershenwald

DECEMBER 6TH 2013

11:10 Break

11:25 Diagnosis and new procedures: innovation and sustainability
Alessandro Testori

11:50 Combination therapies and Surgery in the treatment of metastatic melanoma
Nicola Mozzilo

12:15 Are there systemic benefits to local and regional therapy of metastases in melanoma?
Mark Faries

12:40 Best poster oral presentation on diagnosis and new procedures

13:00 Lunch

MOLECULAR ADVANCES AND COMBINATION THERAPIES

Chair: Paolo A. Ascierto and Giuseppe Palmieri

14:00 Melanoma next-generation sequencing, biological significance and clinical applications
Ruth Halaban

14:25 Biological and clinical implications of cell signaling in melanoma
Richard Marais

14:50 Targeting apoptosis to enhance the effectiveness of BRAF-directed therapy in melanoma
Ryan Sullivan

PRELIMINARY PROGRAM

DECEMBER 6TH 2013

- 15:15 CSF-1 and Erk inhibitors for melanoma
Antoni Ribas
- 15:40 Break
- 16:05 Recent advances in melanoma combination therapy
Igor Puzanov
- 16:30 Combination Therapies: The Solution to Drug Resistance?
James Larkin
- 16:55 LGX818 + MEK162 combination therapy of melanoma and beyond BRAFi/MEKi
Richard Kefford
- 17:20 Best poster oral presentation on molecular advances and combination therapies
- 17:45 Closing remarks

DECEMBER 7TH 2013

DECEMBER 7TH 2013

NEWS IN IMMUNOTHERAPY

Chair: Michele Maio and Giuseppe Masucci

- 9:20 New Approaches to Adjuvant Therapy
John Kirkwood
- 9:50 Escape mechanisms in melanoma
Soldano Ferrone
- 10:15 Understand variants contribute to immune responsiveness
Ena Wang
- 10:40 Distinct strategies of melanoma to evade immune surveillance and induce resistance to targeted therapies
Barbara Seliger
- 11:05 Break
- 11:20 Targeting the Tim-3 pathway in cancer
Ana Carrizosa Anderson
- 11:45 Combinations of Immunotherapy
Steven Hodi

PRELIMINARY PROGRAM

DECEMBER 7TH 2013

12:10 Final Results of the OPTiM Phase III Clinical Trial of Talimogene Laherparepvec and the Role of Oncolytic Virus Therapy for Melanoma
Howard Kaufman

12:35 Recent Advances in Adoptive T Cell Therapies
David Stroncek

13:00 Best poster oral presentation on news in immunotherapy

13:20 Lunch

TUMOR MICROENVIRONMENT AND BIOMARKERS

Chair: Magdalena Thurin and Gennaro Ciliberto

14:30 Signature genes and molecular biomarkers of melanoma predisposition to prometastatic effects of inflammation
Fernando Vidal-Vanaclocha

14:55 Immunotherapies based on CD137
Ignacio Melero

15:20 Inflammation in tumor progression
Alberto Mantovani

15:45 Immunoprofiling responders to immunotherapy
Carlo Bifulco

DECEMBER 7TH 2013

- 16:10 Break
- 16:25 New candidate biomarkers for cytokine and ipilimumab activity
Alexander Eggermont
- 16:50 Mechanisms mediating a T cell-inflamed versus non-inflamed melanoma tumor
microenvironment
Thomas F. Gajewski
- 17:15 The immunological aspects of vemurafenib treatment
Bastian Schilling
- 17:35 Immune gene expression patterns in primary melanoma tumors predict clinical outcomes
Yvonne Saenger
- 17:50 Best poster oral presentation on molecular advances and biomarkers
- 18:10 Closing remarks

PRELIMINARY PROGRAM

DECEMBER 8TH 2013

DECEMBER 8TH 2013

WORLD-WIDE IMMUNOSCORE TASK FORCE: AN UPDATE

Chair: Francesco M. Marincola and Paolo A. Ascierto

9:00 Immunoscore participants round table on recent advances
Lotfi Chouchane
Jerome Galon

11:15 Break

REGULATORY SESSION

*Chair: Pier Luigi Canonico and Sabino De Placido**

11:30 Round Table of Regulatory Issues of Melanoma drugs
Lotfi Chouchane (Qatar)
Francesco De Lorenzo (President of Italian Federation of Volunteer-based Cancer Organizations, FAVO)*
Luca Pani (General Director of the Italian Medicines Agency, AIFA)
Carmine Pinto (President Elect of Associazione Italiana di Oncologia Medica, AIOM)*
Francesco Rossi (President of the Italian Society of Pharmacology, SIF)

13:30 Closing remarks

13:45 CME test

*invited speaker

PRESIDENT and SCIENTIFIC BOARD

PRESIDENTS:

Paolo A. Ascierto

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy

Francesco M. Marincola

Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Nicola Mozzillo

Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy

SCIENTIFIC BOARD:

Paolo A. Ascierto

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy

Lotfi Chouchane

Assistant Dean for Basic Science, Professor of Genetic Medicine, Professor of Microbiology & Immunology, Weill Cornell Medical College, Qatar

Gennaro Ciliberto

Scientific Director of the National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Clause Garbe

University Professor of Dermatology, Head, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen (Stuttgart), Germany

SCIENTIFIC BOARD

John Kirkwood

Professor of Clinical and Translational Science, Clinical and Translational Science Institute, University of Pittsburgh, Pennsylvania

Alberto Mantovani

Scientific Director of Istituto Clinico Humanitas, Milan, Italy

Francesco M. Marincola

Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Giuseppe Masucci

Professor, Department of Oncology-Pathology, and KcRN, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Ignacio Melero

Professor of Immunology and Consultant, CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

Nicola Mozzillo

Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy

Giuseppe Palmieri

Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

Antoni Ribas

Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles, California

David Stroncek

Chief, Cell Processing Section, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Walter Urba

Director cancer research, Earle A. Chiles Research Institute, Providence Cancer Center, Providence, Oregon

Fernando Vidal-Vanaclocha

Professor of Cell Biology and Human Histology, Vice Dean for Research and International Affairs and Scientific Director of the Institute of Applied Molecular Medicine (IMMA) at the CEU-San Pablo University School of Medicine, Madrid, Spain

Ena Wang

Acting Section Head of Infectious Disease and Immunogenetics Section (IDIS); Director of Molecular Science, Department of Transfusion Medicine, CC; Associated director of Center for Human Immunology, NIH, Maryland

FACULTY

FACULTY:

Paolo A. Ascierto

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy

Carlo Bifulco

Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

Pier Luigi Canonico

Department of Scienze del Farmaco, University of Piemonte Orientale, Novara, Italy

Ana Carizzosa Anderson

Assistant Professor at Kuchroo Laboratory, Center for Neurologic Disease Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Lotfi Chouchane

Assistant Dean for Basic Science, Professor of Genetic Medicine, Professor of Microbiology & Immunology, Weill Cornell Medical College, Qatar

Gennaro Ciliberto

Scientific Director of the National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Alistair Cochran

Distinguished Professor of Pathology and Laboratory Medicine, UCLA, California

Francesco De Lorenzo*

President of Italian Federation of Volunteer-based Cancer Organizations, FAVO

Sabino De Placido*

Professor of Medical Oncology, University of Naples, Italy

Alexander Eggermont

Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, France

Mark Faries

Department of Surgical Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California

Soldano Ferrone

University of Pittsburgh, Department of Pathology and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

Thomas F. Gajewski

Department of Pathology and Department of Medicine, Section of Hematology/Oncology, Chicago, Illinois

Jerome Galon

Research Director at INSERM (National Institute of Health and Medical Research), Paris, France

Clause Garbe

University Professor of Dermatology, Head, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen (Stuttgart), Germany

Jeffrey E. Gershenwald

Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas

FACULTY

Ruth Halaban

Director, Yale SPORE in Skin Cancer, Yale University School of Medicine, Department of Dermatology, New Haven, Connecticut

Steven Hodi

Dana-Farber Cancer Institute, Boston, Massachusetts

Howard L. Kaufman

The Tumor Immunology Laboratory & Department of General Surgery, Rush University Medical Center, Chicago, Illinois

Richard Kefford

Professor of Medicine and Director of the Westmead Institute for Cancer Research and Consultant Medical Oncologist to the Sydney Melanoma Unit and the NSW Breast Cancer Institute, Sydney, Australia

John Kirkwood

Professor of Clinical and Translational Science, Clinical and Translational Science Institute, University of Pittsburgh, Pennsylvania

James Larkin

Department of Medicine, The Royal Marsden Hospital, London, UK

Sancy Leachman

Department of Dermatology, Oregon Health & Sciences University, Oregon

Michele Maio

U.O.C. Immunoterapia Oncologica Azienda Ospedaliera Universitaria Senese, Siena, Italy

Alberto Mantovani

Scientific Director of Istituto Clinico Humanitas, Milan, Italy

Richard Marais

Director, Paterson Institute for Cancer Research, Manchester, United Kingdom

Francesco M. Marincola

Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Giuseppe Masucci

Professor, Department of Oncology-Pathology, and KcRN, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Ignacio Melero

Professor of Immunology and Consultant, CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

Nicola Mozzillo

Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy

Giuseppe Palmieri

Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

Luca Pani

General Director, Italian Medicines Agency - AIFA

FACULTY

Carmine Pinto

President Elect of Associazione Italiana di Oncologia Medica, AIOM

Igor Puzanov

Associate Professor of Medicine, Clinical Director, Renal Cancer/Melanoma, Vanderbilt University, Nashville, Tennessee

Antoni Ribas

Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles, California

Yvonne Saenger

Departments of Dermatology, Mount Sinai School of Medicine, New York

Bastian Schilling

Department of Dermatology, University Hospital Essen, Essen, Germany

Barbara Seliger

Institute of Medical Immunology, Martin-Luther-University Halle-Wittenberg, Halle, Saale, Germany

David Stroncek

Chief, Cell Processing Section, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland

Ryan Sullivan

Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Alessandro Testori

Melanoma and muscle-cutaneous sarcomas Division, Istituto Europeo di Oncologia, Milan, Italy

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Fernando Vidal-Vanaclocha

Professor of Cell Biology and Human Histology, Vice Dean for Research and International Affairs and Scientific Director of the Institute of Applied Molecular Medicine (IMMA) at the CEU-San Pablo University School of Medicine, Madrid, Spain

Ena Wang

Acting Section Head of Infectious Disease and Immunogenetics Section (IDIS); Director of Molecular Science, Department of Transfusion Medicine, CC; Associated director of Center for Human Immunology, NIH, Maryland

GENERAL INFORMATION



CME PROVIDER AND ORGANISING AGENCY:

3P Solution Srl
Via Marradi 3, 20123 Milan
Phone +39 02 36631574
Fax +39 02 89098927
www.3psolution.it
info@3psolution.it
info@melanomabridge.org

CONGRESS VENUE:

Royal Continental Hotel
Via Partenope, 38-44
80121 - Naples
Phone +39 081 245 2068
www.royalgroup.it/royalcontinental/

OFFICIAL LANGUAGE:

The official language is English

REGISTRATION:

Only registered attendees will be admitted to the meeting.


The registration fee includes:

- participation in the scientific program
- CME credits
- coffee breaks and lunches from December 6th to 8th
- congress bag

Participants are kindly requested to inform us about any dietary habit (i.e. food allergies/intolerances, vegetarian or vegan habits).

Please visit www.melanomabridge.org for registration.

GENERAL INFORMATION





CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Provider (code 327) and has a quality-management system that meets the requirements of UNI EN ISO 9001:2008, with CSQA certificate no. 23887.

Melanoma Bridge will be accredited by the Italian Ministry of Health

The specialties and disciplines eligible for CME credits are: Medical Doctors, Pharmacists, Biologists, and Nurses.

In order to receive credits, participants must:

1. Attend all the accredited sessions;
2. Complete the assessment test at the end of the congress (a grade of 75% must be obtained to receive CME credit);
3. Complete the evaluation questions at the end of the congress.

CME certificate attendance will be sent to the participants at the end of the evaluation procedure. The educational material related to the event will be available to participants on the website www.3psolution.it upon registration.

ORGANIZED BY



Fondazione Melanoma Onlus



**Istituto Nazionale Tumori - IRCCS
"Fondazione G.Pascale"**



Sidra Medical and Research Center



Society for Immunotherapy of Cancer

Associazione Italiana di Oncologia Medica



European Society for Medical Oncology



Intergruppo Melanoma Italiano



La realizzazione di questo evento è stata possibile grazie ad un unrestricted grant di:

